http://www.fpnotebook.com/
ValproateAka: Valproic Acid, Depakote, Depakene
- Indications
- Generalized Tonic Clonic Seizures
- Absence Seizures
- Myoclonic Seizures
- Simple Partial Seizures
- Complex Partial Seizures
- Migraine Headache Prophylaxis
- Mania
- Contraindications
- Hepatic dysfunction
- Pregnancy
- Urea cycle disorder
- Adverse Effects: Dose related
- Nausea and Vomiting
- Tremor
- Ataxia
- Diarrhea
- Lethargy
- Mild Liver Function Test abnormalities (AST, ALT)
- Adverse Effects
- Pancreatitis
- Alopecia
- Centrum A-Zinc daily prevents associated Hair Loss
- Thrombocytopenia
- Stevens-Johnson Syndrome
- Osteoporosis
- Hepatic dysfunction (in rare cases, may be fatal)
- Dosing: Adults
- Seizure Disorder
- Initial: 10-15 mg/kg/day divided qd - tid
- Increase in 5-10 mg/kg/day increments weekly
- Target dose: 30-60 mg/kg/day to 1000-2500 mg/day
- Divide regular and delayed release dosing bid-qid
- Extended release may be dosed once daily
- Migraine Headache Prophylaxis
- Initial
- Depakote ER 500 mg PO qd for 7 days
- Depakote delayed release 250 mg PO bid
- May increase to 1000 mg/day
- Drug Interactions
- Numerous drug interactions
- Toxicity
- Large therapeutic Window
- Monitoring
- Plasma level correlates with clinical response
- Follow Liver Function Tests
- Pregnancy Risk
- Class D
|
|---|
| Definition (CSP) | fatty acid with anticonvulsant properties. |
| Concepts | Lipid (T119)
, Pharmacologic Substance (T121)
|
| English | 2 propylvalerate, Valproate, VALPROATE PREPARATION, Valproate product |
| Spanish | valproato |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree